Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

Core Insights - Halozyme Therapeutics reported a revenue of $451.77 million for the quarter ended December 2025, marking a 51.6% increase year-over-year, while EPS was -$0.24 compared to $1.26 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $448.62 million by 0.7%, but the EPS fell short of the consensus estimate of $2.15 by 111.16% [1] Revenue Breakdown - Product sales, net reached $122.67 million, surpassing the average estimate of $115.69 million by analysts, reflecting a year-over-year increase of 54.6% [4] - Royalties amounted to $257.97 million, slightly below the estimated $262.14 million, but still showing a 51.4% increase compared to the previous year [4] - Revenues from collaboration agreements were reported at $71.13 million, exceeding the average estimate of $61.31 million, representing a 47.5% year-over-year growth [4] Stock Performance - Over the past month, shares of Halozyme Therapeutics have returned +11.6%, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]